Multidisciplinary focus on cyclosporin a

Journal of Rheumatology

Volumn 36, Issue SUPPL. 83, 2009, Pages 52-55

  Salvarani, Carlo ^a,c   Boiardi, Luigi ^a   Macchioni, Pierluigi ^a   Pipitone, Nicolò ^a   Catanoso, Mariagrazia ^a   Pigatto, Paolo ^b  

^a S MARIA NUOVA HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c Servizio di Reumatologia   (Italy)

Author keywords

Cyclosporin A; Psoriasis; Psoriatic arthritis

Indexed keywords

CREATININE; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; SALAZOSULFAPYRIDINE; VASCULOTROPIN; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; CREATININE BLOOD LEVEL; DACTYLITIS; DISEASE DURATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; KIDNEY INJURY; LONG TERM CARE; MONOTHERAPY; NEPHROTOXICITY; PALLIATIVE THERAPY; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; SHORT COURSE THERAPY; SIDE EFFECT; SYNOVITIS; TREATMENT RESPONSE; ARTICLE;

ARTHRITIS, PSORIATIC; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 70349907644     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090225     Document Type: Conference Paper

References (29)

1. Madan V, Griffiths CE. Systemic cyclosporin and tacrolimus in dermatology. Dermatol Ther 2007;20:239-250
2. Mozzanica N, Pigatto PD, Finzi AF. Cyclosporin in psoriasis: pathophysiology and experimental data. Dermatology 1993;187 Suppl 1:3-7. (Pubitemid 23223842)
3. Finzi AF, Mozzanica N, Cattaneo A, Chiappino G, Pigatto PD. Effectiveness of cyclosporine treatment in severe psoriasis: a clinical and immunologic study. J Am Acad Dermatol 1989;21:91-97 (Pubitemid 19171472)
4. Ho VCY, Griffiths CEM, Albrecht G, et al. Intermittent short courses of cyclosporin (Neoral) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomised study. Br J Dermatol 1999;141:283-291 (Pubitemid 29397997)
5. Ho VCY, Griffiths CEM, Berth-Jones J, et al. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol 2001;44:643-651 (Pubitemid 32249523)
6. Ellis CN, Fradin MS, Hamilton TA, Voorhees JJ. Duration of remission during maintenance cyclosporine therapy for psoriasis. Relationship to maintenance dose and degree of improvement during initial therapy. Arch Dermatol 1995;131:791-795
7. Koo J, for the OLP302 Study Group. A randomised, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. Br J Dermatol 1998;139:88-95. (Pubitemid 28338069)
8. Fradin MS, Ellis CN, Voorhees JJ, et al. Rapid response of von Zumbusch psoriasis to cyclosporine. J Am Acad Dermatol 1990;23:925-926
9. Salvarani C, Olivieri I, Cantini F,Macchioni L, Boiardi L. Psoriatic arthritis. Curr Opin Rheumatol 1998;10:299-305.
10. Salvarani C, Cantini F, Olivieri I. Disease-modifying antirheumatic drug therapy for psoriatic arthritis. Clin Exp Rheumatol 2002;20 Suppl 28:S71-5. (Pubitemid 35190007)
11. Olivieri I, Salvarani C, Cantini F, et al. Therapy with cyclosporine in psoriatic arthritis. Semin Arthritis Rheum 1997;27:36-43.
12. Kavanaugh AF, Ritchlin CT; GRAPPA Treatment Guideline Committee. Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol 2006;33:1417-1421
13. Spadaro A, Riccieri V, Sili-Scavalli A, Sensi F, Taccari E, Zoppini A. Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol 1995;13:589-593
14. Fraser AD, van Kuijk AW, Westhovens R, et al. A randomised, double-blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 2005;64:859-864 (Pubitemid 40733909)
15. Salvarani C, Macchioni P, Olivieri I, et al. A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 2001;28:2274-2282 (Pubitemid 32947875)
16. Ho S, Clipstone N, Timmermann L, et al. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol 1996;80:S40-5.
17. Hernandez GL, Volpert OV, Iñiguez MA, et al. Selective inhibition of vascular endothelial growth factor mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated T cells and cyclooxygenase 2. J Exp Med 2001;193:607-620
18. Reece RJ, Canete JD, Parsons WJ, Emery P, Veale DJ. Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis. Arthritis Rheum 1999;42:1481-1484 (Pubitemid 30265607)
19. Fearon U, Reece R, Smith J, Emery P, Veale DJ. Synovial cytokine and growth factor regulation of MMPs/TIMPs: implications for erosions and angiogenesis in early rheumatoid and psoriatic arthritis patients. Ann NY Acad Sci 1999;878:619-621 (Pubitemid 29353629)
20. Ballara S, Taylor PC, Reusch P, et al. Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum 2001;44:2055-2064 (Pubitemid 33644048)
21. Boiardi L, Salvarani C, Macchioni P, et al. Immunologic effects in patients with psoriatic arthritis treated with cyclosporine A. J Rheumatol 1992;19:1933-1937 (Pubitemid 23018527)
22. Macchioni P, Boiardi L, Meliconi R, et al. Serum chemokines in patients with psoriatic arthritis treated with cyclosporin A. J Rheumatol 1998;25:320-325 (Pubitemid 28088263)
23. Salvarani C,Macchioni P, Boiardi L, et al. Low dose cyclosporine A in psoriatic arthritis: relation between soluble interleukin 2 receptors and response to therapy. J Rheumatol 1992;19:74-79
24. Macchioni P, Boiardi L, Cremonesi T, et al. The relationship between serum-soluble interleukin-2 receptor and radiological evolution in psoriatic arthritis patients treated with cyclosporin A. Rheumatol Int 1998;18:27-33. (Pubitemid 28301545)
25. Sarzi-Puttini P, Cazzola M, Panni B, et al. Long-term safety and efficacy of low-dose cyclosporin A in severe psoriatic arthritis. Rheumatol Int 2002;21:234-238 (Pubitemid 34328058)
26. Feutren G, Mihatsch MJ. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. N Engl J Med 1992;326:1654-1660
27. Landewe RB, Goei The HS, van Rijthoven AW, Rietveld JR, Breedveld FC, Dijkmans BA. Cyclosporine in common clinical practice: an estimation of the benefit/risk ratio in patients with rheumatoid arthritis. J Rheumatol 1994;21:1631-1636
28. Rodriguez F, Krayenbühl JC, Harrison WB, et al. Renal biopsy findings and followup of renal function in rheumatoid arthritis patients treated with cyclosporin A. An update from the International Kidney Biopsy Registry. Arthritis Rheum 1996;39:1491-1498
29. Pasero G and the GRISAR group. Assessment of side effects of low cyclosporin doses in early rheumatoid arthritis after three years [abstract]. Arthritis Rheum 1997;40 Suppl:S96.